Hayder Kadhim: Determinants and Outcomes of OAC Discontinuation in Atrial Fibrillation
Hayder Kadhim, Consultant Cardiologist at Region Östergötland, shared a post on LinkedIn:
”I am pleased and honored to present our latest study as a poster at the prestigious ESOC Conference in Maastricht.
Our research explores risk factors associated with oral anticoagulant (OAC) interruptions in patients with non-valvular atrial fibrillation (NVAF), including both temporary and permanent discontinuations.
We also examine treatment pattern changes across different OAC types and dosing strategies, and compare clinical outcomes between patients who persist with therapy and those who discontinue.
This work is based on high-quality Swedish national registers, including AURICULA, which uniquely enabled us to identify the exact dates of treatment discontinuation and generate robust real-world evidence.”
Stay updated with Hemostasis Today.
-
May 8, 2026, 17:11Drazen Perkov: Complication Management in Endovascular Thrombectomy
-
May 8, 2026, 17:07Basel Saber: New Evidence on Stroke Prevention in Post-Operative Atrial Fibrillation
-
May 8, 2026, 17:00Adriana Skafi: Case Report on Catastrophic Antiphospholipid Syndrome
-
May 8, 2026, 16:43Panagiotis Iliakis: The ANDAMAN Trial and the Challenge of Aspirin Resistance
-
May 8, 2026, 16:36Ali AlBahar: Why Blood Groups Matter
-
May 8, 2026, 16:27Tanmay Banerjee: Laboratory Error Safety in Hematology Testing
-
May 8, 2026, 16:26Nadishani Ratnayake: Supporting Safer Anticoagulation Care With Digital Tools
-
May 8, 2026, 16:15Jim Hoffman: Thrombomodulin as a Key Regulator of Coagulation and Inflammation
-
May 8, 2026, 16:09Panagiotis Christoforou: Honoured to Receive the ASH Clinical News Reader Response Prize